AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine

AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine
AIVITA Biomedical has begun to randomize patients for a Phase 2 clinical trial assessing its cell-based immunotherapy for the treatment of newly-diagnosed advanced ovarian cancer. Currently recruiting participants at Hoag Memorial Hospital Presbyterian in California, the study is expected to enroll 99 patients who will receive AIVITA's patient-specific ovarian cancer vaccine or a placebo. AIVITA's immunotherapy uses a patient's own dendritic cells, which are boosted to fight the tumor by exposure to tumor proteins. Dendritic cells are cells of our immune system that present certain proteins to T-cells, telling them what their targets should be. Thus, researchers join patient’s dendritic and tumor cells in the lab, making the dendritic cells present cancer-specific proteins at their surface. When injected back into the patient, these will re-educate T-cells to react against any cancer cells. Because this broader strategy also will target tumor-initiating cells — key cells in cancer growth and spread ing — researchers believe it will work better than other dendritic cell therapies that present only a subset of cancer proteins. The Phase 2 trial (NCT02033616) will enroll women with stage 3 or 4 epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who have received surgery to remove their tumor, and who have started or completed standard chemotherapy regimens. For a patient to be eligible, the tumor specimen removed during surgery must have been stored. Also, patients must have
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *